Online inquiry

IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14854MR)

This product GTTS-WQ14854MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14854MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11207MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ3514MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ12134MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ2929MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ13534MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ8413MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ1288MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ3070MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW